Skip to Main Content

Paper Details

A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.
Cell Rep Med
53
2020
ALI, ARDS, Acute Lung Injury, Fostamatinib, MUC1, Mucin-1, R406, R788, SARS-CoV-2, SYK, acute lung injury, acute respiratory distress syndrome, chronic immune thrombocytopenia, fostamatinib, lung epithelial cells, mouse, mucin-1, spleen tyrosine kinase, tyrosine
Author NameAffiliation
Maria Kost-AlimovaThe Broad Institute of MIT and Harvard
Eriene-Heidi SidhomThe Broad Institute of MIT and Harvard
Eriene-Heidi SidhomBrigham and Women's Hospital and Harvard Medical School
Moran Dvela-LevittThe Broad Institute of MIT and Harvard
Moran Dvela-LevittBrigham and Women's Hospital and Harvard Medical School
Seth L AlperThe Broad Institute of MIT and Harvard
Seth L AlperBeth Israel Deaconess Medical Center and Harvard Medical School
Ayshwarya SubramanianThe Broad Institute of MIT and Harvard
Ayshwarya SubramanianThe Broad Institute of MIT and Harvard
Choah KimThe Broad Institute of MIT and Harvard
Choah KimBrigham and Women's Hospital and Harvard Medical School
Jamie L MarshallThe Broad Institute of MIT and Harvard
Juan Lorenzo PabloThe Broad Institute of MIT and Harvard
Astrid WeinsBrigham and Women's Hospital and Harvard Medical School
Jillian L ShawThe Broad Institute of MIT and Harvard
Anna GrekaThe Broad Institute of MIT and Harvard
Anna GrekaBrigham and Women's Hospital and Harvard Medical School
  • 1 - 17

Datasets

Release 1.2